Abstract

Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen
and colleagues report a randomised, placebo-controlled, multiple-dose trial using
a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive
results in terms of evolution of pain for up to 12 weeks, in line with the former
trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed,
however, in a subgroup of patients with high level of pain at baseline. Although these
data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as
limited intraarticular anti-IL-1 delivery should still be considered.